10 research outputs found

    Diseño de plan de mercadeo estratégico para la empresa Ángel Dorado Spa Estética Profesional

    Get PDF
    El presente plan estratĂ©gico de mercadeo se realiza en la compañía ÁNGEL DORADO SPA, ubicada en el sector de La Hacienda al sur de la ciudad de Cali, para el año 2017. Este proyecto compete a la estrategia y mejora de un establecimiento de servicios estĂ©ticos que se ha forjado arduamente a travĂ©s de su corta experiencia en el mercado, se busca orientarlo a la oportunidad de un mercado en el que la salud integral se ve como un estereotipo de vanidad y no como un complemento a la estabilidad fĂ­sica, mental y espiritual, basado en las nuevas tendencias del consumidor moderno, el cual busca siempre servicios saludables y que promueva un estilo de vida menos dañino, y asĂ­ ejercer la responsabilidad de orientar el mercado a servicios mĂĄs integrales (medio ambiente y la salud). Este fenĂłmeno se considera como mercado fitness, dado que estĂĄ directamente relacionado con el entorno, el deporte, y la nutriciĂłn. Realizando un barrido entre el entorno y la empresa misma, se cuenta con una competencia amplia respecto a servicios y trayectoria, pero sin fuertes conceptos de salud integral. En Ángel Dorado Spa, se identifican falencias internas como una estructura administrativa y gerencial inadecuada, la cual se refleja en un dĂ©bil direccionamiento financiero y baja competitividad, sin embargo, es importante resaltar como fortaleza, la percepciĂłn de satisfacciĂłn que manifiestan sus clientes y el uso de equipos de Ășltima tecnologĂ­a. Dentro del portafolio de servicios del Spa, se encuentran tratamientos faciales, corporales, cĂĄmaras de bronceo, masajes y depilaciĂłn, todo esto apoyado con equipos de Ășltima tecnologĂ­a, para que sus clientes estĂ©n completamente satisfechos y esto se vea reflejada en su diario vivir. En el desarrollo de este trabajo se buscarĂĄ identificar las posibles opciones con las que podrĂĄ contar la empresa para mejorar la competitividad en el mercado, puesto que ha funcionado de forma empĂ­rica desde el momento en que fue creada en el sector servicios. PermitirĂĄ crear un panorama que evidencie sus fortalezas y falencias, logrando un direccionamiento y estrategias que generan un entorno competitivo, incrementando las ventas y mejorando su posiciĂłn en el mercadoProyecto de grado (Profesional en Mercadeo y Negocios Internacionales)-- Universidad AutĂłnoma de Occidente, 2016PregradoProfesional en Mercadeo y Negocios Internacionale

    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Get PDF
    Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

    Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

    Get PDF
    Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

    Diseño de plan de mercadeo estratégico para la empresa Ángel Dorado Spa Estética Profesional

    No full text
    El presente plan estratĂ©gico de mercadeo se realiza en la compañía ÁNGEL DORADO SPA, ubicada en el sector de La Hacienda al sur de la ciudad de Cali, para el año 2017. Este proyecto compete a la estrategia y mejora de un establecimiento de servicios estĂ©ticos que se ha forjado arduamente a travĂ©s de su corta experiencia en el mercado, se busca orientarlo a la oportunidad de un mercado en el que la salud integral se ve como un estereotipo de vanidad y no como un complemento a la estabilidad fĂ­sica, mental y espiritual, basado en las nuevas tendencias del consumidor moderno, el cual busca siempre servicios saludables y que promueva un estilo de vida menos dañino, y asĂ­ ejercer la responsabilidad de orientar el mercado a servicios mĂĄs integrales (medio ambiente y la salud). Este fenĂłmeno se considera como mercado fitness, dado que estĂĄ directamente relacionado con el entorno, el deporte, y la nutriciĂłn. Realizando un barrido entre el entorno y la empresa misma, se cuenta con una competencia amplia respecto a servicios y trayectoria, pero sin fuertes conceptos de salud integral. En Ángel Dorado Spa, se identifican falencias internas como una estructura administrativa y gerencial inadecuada, la cual se refleja en un dĂ©bil direccionamiento financiero y baja competitividad, sin embargo, es importante resaltar como fortaleza, la percepciĂłn de satisfacciĂłn que manifiestan sus clientes y el uso de equipos de Ășltima tecnologĂ­a. Dentro del portafolio de servicios del Spa, se encuentran tratamientos faciales, corporales, cĂĄmaras de bronceo, masajes y depilaciĂłn, todo esto apoyado con equipos de Ășltima tecnologĂ­a, para que sus clientes estĂ©n completamente satisfechos y esto se vea reflejada en su diario vivir. En el desarrollo de este trabajo se buscarĂĄ identificar las posibles opciones con las que podrĂĄ contar la empresa para mejorar la competitividad en el mercado, puesto que ha funcionado de forma empĂ­rica desde el momento en que fue creada en el sector servicios. PermitirĂĄ crear un panorama que evidencie sus fortalezas y falencias, logrando un direccionamiento y estrategias que generan un entorno competitivo, incrementando las ventas y mejorando su posiciĂłn en el mercadoProyecto de grado (Profesional en Mercadeo y Negocios Internacionales)-- Universidad AutĂłnoma de Occidente, 201

    Global impact of the first coronavirus disease 2019 (COVID-19) pandemic wave on vascular services

    No full text
    This online structured survey has demonstrated the global impact of the COVID-19 pandemic on vascular services. The majority of centres have documented marked reductions in operating and services provided to vascular patients. In the months during recovery from the resource restrictions imposed during the pandemic peaks, there will be a significant vascular disease burden awaiting surgeons. One of the most affected specialtie

    Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study

    No full text
    Background: Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. The aims of this study were to quantify the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic; and to evaluate whether delays in surgery led to an increased occurrence of aggressive tumours. Methods: In this retrospective, international, cross-sectional study, centres were invited to participate in June 22, 2022; each centre joining the study was asked to provide data from medical records on all surgical thyroidectomies consecutively performed from Jan 1, 2019, to Dec 31, 2021. Patients with indeterminate thyroid nodules were divided into three groups according to when they underwent surgery: from Jan 1, 2019, to Feb 29, 2020 (global prepandemic phase), from March 1, 2020, to May 31, 2021 (pandemic escalation phase), and from June 1 to Dec 31, 2021 (pandemic decrease phase). The main outcomes were, for each phase, the number of surgeries for indeterminate thyroid nodules, and in patients with a postoperative diagnosis of thyroid cancers, the occurrence of tumours larger than 10 mm, extrathyroidal extension, lymph node metastases, vascular invasion, distant metastases, and tumours at high risk of structural disease recurrence. Univariate analysis was used to compare the probability of aggressive thyroid features between the first and third study phases. The study was registered on ClinicalTrials.gov, NCT05178186. Findings: Data from 157 centres (n=49 countries) on 87 467 patients who underwent surgery for benign and malignant thyroid disease were collected, of whom 22 974 patients (18 052 [78·6%] female patients and 4922 [21·4%] male patients) received surgery for indeterminate thyroid nodules. We observed a significant reduction in surgery for indeterminate thyroid nodules during the pandemic escalation phase (median monthly surgeries per centre, 1·4 [IQR 0·6-3·4]) compared with the prepandemic phase (2·0 [0·9-3·7]; p<0·0001) and pandemic decrease phase (2·3 [1·0-5·0]; p<0·0001). Compared with the prepandemic phase, in the pandemic decrease phase we observed an increased occurrence of thyroid tumours larger than 10 mm (2554 [69·0%] of 3704 vs 1515 [71·5%] of 2119; OR 1·1 [95% CI 1·0-1·3]; p=0·042), lymph node metastases (343 [9·3%] vs 264 [12·5%]; OR 1·4 [1·2-1·7]; p=0·0001), and tumours at high risk of structural disease recurrence (203 [5·7%] of 3584 vs 155 [7·7%] of 2006; OR 1·4 [1·1-1·7]; p=0·0039). Interpretation: Our study suggests that the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic period could have led to an increased occurrence of aggressive thyroid tumours. However, other compelling hypotheses, including increased selection of patients with aggressive malignancies during this period, should be considered. We suggest that surgery for indeterminate thyroid nodules should no longer be postponed even in future instances of pandemic escalation. Funding: None

    Observation of the rare Bs0oÎŒ+Ό−B^0_so\mu^+\mu^- decay from the combined analysis of CMS and LHCb data

    No full text

    Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    No full text
    non present

    Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries

    Get PDF
    Background Anastomotic leak affects 8 per cent of patients after right colectomy with a 10-fold increased risk of postoperative death. The EAGLE study aimed to develop and test whether an international, standardized quality improvement intervention could reduce anastomotic leaks. Methods The internationally intended protocol, iteratively co-developed by a multistage Delphi process, comprised an online educational module introducing risk stratification, an intraoperative checklist, and harmonized surgical techniques. Clusters (hospital teams) were randomized to one of three arms with varied sequences of intervention/data collection by a derived stepped-wedge batch design (at least 18 hospital teams per batch). Patients were blinded to the study allocation. Low- and middle-income country enrolment was encouraged. The primary outcome (assessed by intention to treat) was anastomotic leak rate, and subgroup analyses by module completion (at least 80 per cent of surgeons, high engagement; less than 50 per cent, low engagement) were preplanned. Results A total 355 hospital teams registered, with 332 from 64 countries (39.2 per cent low and middle income) included in the final analysis. The online modules were completed by half of the surgeons (2143 of 4411). The primary analysis included 3039 of the 3268 patients recruited (206 patients had no anastomosis and 23 were lost to follow-up), with anastomotic leaks arising before and after the intervention in 10.1 and 9.6 per cent respectively (adjusted OR 0.87, 95 per cent c.i. 0.59 to 1.30; P = 0.498). The proportion of surgeons completing the educational modules was an influence: the leak rate decreased from 12.2 per cent (61 of 500) before intervention to 5.1 per cent (24 of 473) after intervention in high-engagement centres (adjusted OR 0.36, 0.20 to 0.64; P < 0.001), but this was not observed in low-engagement hospitals (8.3 per cent (59 of 714) and 13.8 per cent (61 of 443) respectively; adjusted OR 2.09, 1.31 to 3.31). Conclusion Completion of globally available digital training by engaged teams can alter anastomotic leak rates. Registration number: NCT04270721 (http://www.clinicaltrials.gov)
    corecore